Drugmaker AMDL ( ADL) announced that its China subsidiary Jade Pharmaceutical received approval from regulators there for its antibiotic levofloxacin.

The drug, which will be used to treat conditions like pneumonia and urinary tract infections, belongs to a class of drugs called fluoroquinolones. AMDL says the group represents the fastest-growing type of antibacterials in terms of revenue and is being used increasingly to treat a broad range of infections.

The market for fluoroquinolones is dominated by Bayer's ( BAY) drug Cipro and Levaquin, made by Johnson & Johnson ( JNJ) company Ortho-McNeil.